MYOM2 and neoplasm: For example, a DC-based vaccination approach that loaded DCs with an OV, M protein mutant oncolytic VSV (ΔM51-VSV) encoding a tumor-associated antigen, enhanced the activation, maturation, and function of DCs, and subsequently controlled tumor growth by the engagement of both NK and CD8+ T cells [184].